Prolyl endopeptidase FAP

BE0003507ProteinHumansFAP

Cell surface glycoprotein serine protease that participates in extracellular matrix degradation and involved in many cellular processes including tissue remodeling, fibrosis, wound healing, inflammation and tumor growth. It is acted on by 10 drugs in DrugBank.

Gene name
FAP
UniProtKB entry
Q12884Swiss-Prot
Cellular location
Cell surface
Residues / weight
760 residues · 87,712 Da
Also known as
170 kDa melanoma membrane-bound gelatinase · 3.4.21.26 · Dipeptidyl peptidase FAP · FAPalpha · Fibroblast activation protein alpha

Resolves to

Protein
UniProtQ12884UniProt nameSEPR_HUMAN
Gene
HGNCHGNC:3590NCBI Gene2191GeneCardsFAP
Pharmacology
IUPHAR/GtoPdb2365KEGGhsa:2191
Structure
PDB1Z68PDB6Y0FPDB9DVQ
Drugs

What you can answer from here — as of September 03, 2024

10DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
2Clinical trialsTrials of drugs acting on it, by phase and status
Sign in
6GO termsFunction, process and component, as structured annotations
Sign in
2Pfam domainsDomain architecture mapped to Pfam families and clans
Sign in
52+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on Prolyl endopeptidase FAP, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In